Firm hopes to better the therapeutic profile of its antibody candidate.



Merck Serono plans to use Biolex Therapeutics’ LEX System to evaluate antibody optimization and production. Merck Serono will investigate whether this platform has the ability to improve therapeutic profiles of its antibody candidate through optimization of antibody glycosylation structures.


Biolex engineered the LEX System to produce antibodies with a fully human glycosylation structure without fucose. The technology also has the ability to produce antibodies that have a fully G0 glycosylation structure, lacking galactose, the company adds. These two innovations reportedly produce antibodies with greater efficacy and potency, less side effects, and reduced infusion times.








This site uses Akismet to reduce spam. Learn how your comment data is processed.